Back to search

McMaster University

Innovative chromatography and ultrafiltration techniques for enhancing efficiency of large biotherapeutics purification process

Abstract

dc:description.abstract

Biopharmaceutical industry is evolving rapidly with development of biotherapeutic modalities. The approval of some of these products has already demonstrated their potential in the diverse domains such as oncology therapy, gene and cell therapy, vaccines. The large modalities encompass wide range of products such as monoclonal antibodies and related products, gene therapy products, mRNA modalities, virus like particles that are significantly larger than classical therapeutics. However, there are some challenges related to their manufacturing in terms of high dosage, purity and efficiency. Low efficiency in purification of large biotherapeutics largely arises due to steric hindrance, slow mass transfer kinetics, and shear sensitivity. Advancement in column design and purification techniques is one of the key approaches to improve the efficiency of purification processes. Focused on developing and improving chromatography and ultrafiltration processes for purification of large biotherapeutics, this thesis revolves around different aspects of downstream processing of innovative biologics. It describes combining different separation mechanisms in terms of mixed mode chromatography approach using a z2 cuboid device for purification of monoclonal antibody as a scalable, efficient method for removal of monoclonal antibody aggregates. It also describes key role of chromatography column design in efficiency of purification process followed by a generic and faster approach of using size exclusion chromatography (SEC) with z2 cuboid device for separation of monoclonal antibody aggregates from monomers. Furthermore, the same chromatography device demonstrated better resolution at higher process flow rates and sample volumes. Due to the higher efficiency the SEC with z2 cuboid device, the process was paired with membrane chromatography for complete purification of vaccine candidate SARS COV 2 spike protein. Moreover, the thesis reports the development of continuous size exclusion chromatography process named alternating flow SEC for purification of SARS CoV 2 spike protein which significantly improved productivity of regular SEC. Beyond size exclusion chromatography, the thesis addresses some limitations of classic ultrafiltration techniques such as degradation of product, scalability and dedicated setup. A novel carrier phase ultrafiltration and backflow recovery was developed for purification of large biologics which facilitated online monitoring and controlled concentration polarization. Through optimization study of volumetric flux, sample volume and carrier phase composition substantial improvement in process efficiency was achieved. The carrier phase ultrafiltration and backflow recovery technique was scaled up and applied for purification as well as concentration enrichment of SARS CoV 2 virus like particles (VLPs) displaying full length spike protein on their surface. The ultrafiltration step was associated with size exclusion chromatography step to achieve better purity of VLPs. It is anticipated that the contributions herein described will help address unresolved inquiries related to large biotherapeutic purification and thus enable the development of the efficient processes at various downstream processing scales.

Degree

thesis:*
Department dc:contributor.department
Chemical Engineering
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Ingawale, Mrunal Rajendra
Advisor dc:contributor.advisor
  • Ghosh, Raja

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
McMaster University
Base URL
macsphere.mcmaster.ca/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Ingawale, Mrunal Rajendra. Innovative chromatography and ultrafiltration techniques for enhancing efficiency of large biotherapeutics purification process. 2026. https://hdl.handle.net/11375/33790